Clinical Data on Eisai Inc.'s Oncology Pipeline to be Presented at American Society of Clinical Oncology Annual Meeting
WOODCLIFF LAKE, N.J., May 31 /PRNewswire/ -- Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.
These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.
The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year's ASCO meeting.
Product Abstract Details Location Details Eribulin Phase II Study of Eribulin Mesylate June 2, 2007 8:00 Mesylate (E7389) Halichondrin B Analog in AM - 1:00 PM (E7389) Patients with Refractory Breast Cancer Location: S403 Abstract No: Poster Number: 21 1034 Eribulin Phase II Study of Eribulin Mesylate June 2, 2007 8:00 Mesylate (E7389), a Mechanistically Novel AM - 1:00 PM (E7389) Inhibitor of Microtubule Dynamics, Location: E451a Abstract No: in Patients with Advanced Non-Small 7546 Cell Lung Cancer (nsclc) Poster Number: 20 MORAb-003 Novel Phase II Study Design of June 2, 2007 Abstract No: MORAb-003, a Monoclonal Antibody 2:00 PM - 6:00 PM 5583 against Folate Receptor Alpha in Location: S Hall A2 Platinum-Sensitive Ovarian Cancer in First Relapse Poster Number: U4 MORAb-003 A Phase I Study of MORAb-003, a Fully June 2, 2007 Abstract No: Humanized Monoclonal Antibody against 2:00 PM - 6:00 PM 5553 Folate Receptor Alpha, in Advanced Location: S Hall A2 Epithelial Ovarian Cancer Poster Number: R7 E7974 A Phase I Trial of E7974 Administered June 3, 2007 Abstract No: on Days 1 and 15 of a 28-Day Cycle in 8:00 AM - 12:00 PM 2550 Patients With Solid Malignancies Location: S Hall A2 Poster Number: B6 E7974 A Phase I Trial of E7974 Administered June 3, 2007 Abstract No: on Days 1, 8, and 15 of a 28-Day Cycle 8:00 AM - 12:00 PM 2543 in Patients With Solid Malignancies Location: S Hall A2 Poster Number: A13
The expansion of Eisai's oncology discovery, research and clinical development capabilities complements the company's establishment of its oncology sales and marketing operations in the United States. Through its acquisition in 2006 of four marketed oncology products, Eisai also obtained key oncology personnel and expertise, including a sales force. Most recently, Eisai acquired Morphotek, Inc., which discovers and develops therapeutic monoclonal antibodies through its proprietary technologies. Morphotek has preclinical and clinical development programs underway in several therapeutic categories, including oncology. Both acquisitions expand Eisai's capabilities into the biologic therapeutics field.
Eisai is committed to building its commercial oncology infrastructure and is well positioned to market new oncology products that originate from its research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities. That growth will help Eisai address the unmet medical needs of patients, especially cancer patients, throughout the world.
About Eisai Inc.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007).
Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit http://www.eisai.com.
About Eisai Medical Research Inc.
Eisai Medical Research Inc., a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., headquartered in Ridgefield Park, NJ, is focused on clinical drug development of new chemical entities and of new indications for marketed products.
About Morphotek, Inc.
Morphotek(R), Inc., a U.S. subsidiary of Eisai Co., Ltd., was acquired by Eisai in April 2007. Founded in 2000 and located in Exton, PA, Morphotek is a biopharmaceutical company which discovers and develops monoclonal antibodies through the use of proprietary human antibody technology called Human MORPHODOMA(R). Morphotek has assembled a strong pipeline of lead products in the areas of oncology and inflammation and infectious diseases. It has programs in clinical development and in preclinical stage moving towards IND filing. For further information, visit http://www.morphotek.com.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 9,000 people worldwide.Eisai
CONTACT: Judee Shuler of Eisai, during ASCO: +1-908-337-2540, or office:+1-201-746-2241